Key Takeaways
- Standard Dosage Range: Thymosin Alpha-1 is typically administered in doses ranging from 1.6 mg to 3.2 mg per week, depending on the form and therapeutic goal.
- Administration Method: Most commonly delivered via subcutaneous injection, though alternative forms exist.
- Typical Cycle Length: Commonly used in cycles of 4 to 12 weeks, with variations based on specific treatment goals.
- Regulatory Status: Not FDA-approved in the US, but approved in other countries as thymalfasin (Zadaxin) for hepatitis B and C. It was placed in FDA Category 2 in 2023 and removed in September 2024 after the nomination was withdrawn — which is not the same as being cleared for compounding.
- Medical Supervision: Essential for determining the appropriate dosage and monitoring for potential side effects.
How Thymosin Alpha-1 Works in the Body
Thymosin Alpha-1 is a synthetic polypeptide consisting of 28 amino acids, derived from the thymic hormone thymosin fraction 5. Its primary mechanism of action involves modulation of the immune system, specifically through interactions with the MyD88/NF-κB signaling pathway. This interaction plays a crucial role in immune homeostasis and T-cell function.
The peptide binds to receptors that activate the MyD88-dependent signaling cascade, leading to enhanced T-cell responses and modulation of cytokine production. This mechanism is particularly relevant in conditions involving immune dysregulation, such as chronic infections and cancer. The half-life of Thymosin Alpha-1 is approximately 2 hours, with bioavailability dependent on the route of administration.
"Thymosin Alpha-1 significantly reverses M2 polarization of IL10-producing tumor-associated macrophages during efferocytosis." (PMID 35364609)
"TA1 is thought to modulate the immune system by augmenting T-cell function." (PMID 11381492)
These pharmacokinetic properties underscore the importance of precise dosing to achieve therapeutic effects without adverse outcomes.
Standard Thymosin Alpha-1 Dosage Ranges (By Form)
Subcutaneous Injection
- Dosage Range: 1.6 mg to 3.2 mg per week, divided into 2-3 doses.
- Frequency: Typically administered 2-3 times per week.
- Bioavailability: High, as subcutaneous injections bypass first-pass metabolism.
- Common Usage: Preferred due to ease of administration and consistent absorption.
Intramuscular Injection
- Dosage Range: Similar to subcutaneous, though less commonly used.
- Frequency & Bioavailability: Comparable to subcutaneous with minor variations in absorption rates.
Oral Administration
- Dosage Range: Not commonly used due to low bioavailability; typically higher doses required to achieve therapeutic levels.
- Frequency: Daily dosing may be necessary.
- Bioavailability: Significantly lower compared to injectable forms.
Subcutaneous administration remains the most common due to its balance of efficacy and convenience. Clinical protocols often favor this route for its reliable absorption and patient compliance.
Thymosin Alpha-1 Dosage by Use Case
Chronic Hepatitis B
- Typical Dosage Range: 1.6 mg to 3.2 mg per week.
- Administration Method: Subcutaneous injection.
- Cycle Length: 6 to 12 months, often in combination with antiviral therapy.
- Clinical Reference: Thymosin Alpha-1 has been studied in combination with nucleos(t)ide analogs for enhancing T-cell response in chronic hepatitis B patients (PMID 25640173).
Cancer Immunotherapy
- Typical Dosage Range: 1.6 mg to 3.2 mg per week.
- Administration Method: Subcutaneous injection.
- Cycle Length: 8 to 12 weeks, with potential for longer-term use depending on response.
- Practical Guidance: Many clinics prescribe Thymosin Alpha-1 as part of a broader immunotherapeutic regimen to modulate tumor microenvironments.
Age-Related Immune Decline
- Typical Dosage Range: 1.6 mg per week.
- Administration Method: Subcutaneous injection.
- Cycle Length: 4 to 8 weeks, with periodic reassessment.
- Clinical Reference: Studies indicate Thymosin Alpha-1's potential to enhance thymic output and T-cell differentiation in aging populations (PMID 41373628).
How Long Should You Take Thymosin Alpha-1?
The typical treatment duration for Thymosin Alpha-1 ranges from 4 to 12 weeks, depending on the therapeutic goal and patient response. Initial effects may be observed within the first few weeks, with more pronounced outcomes often requiring extended administration.
- Week 1: Initial immune modulation begins; some patients report mild improvements in symptoms.
- Weeks 2-4: Enhanced T-cell activity and cytokine modulation become more evident.
- Week 6+: Continued improvement in immune function, with potential stabilization of therapeutic effects.
Tapering is generally not required, but ongoing assessment by a healthcare provider is crucial to determine the need for continuation or cessation of therapy. Clinical trials often inform these cycle lengths, though individual variation is common.
Administration Protocol: How to Take Thymosin Alpha-1
Injection Technique
- Needle Gauge: 29-31 gauge is recommended for subcutaneous injections.
- Injection Sites: Rotate between the abdomen, thigh, and upper arm to minimize tissue irritation.
- Rotation Schedule: Change injection sites with each administration to prevent localized tissue damage.
Storage Requirements
- Temperature: Store vials at 2-8°C (36-46°F) before reconstitution.
- Light Sensitivity: Protect from light exposure.
- Stability: Once reconstituted, the solution should be used within 14 days if stored properly.
Reconstitution Instructions
- Diluent: Use bacteriostatic water for injection.
- Process: Gently swirl the vial to mix; avoid shaking vigorously.
Step-by-Step Administration
- Preparation: Wash hands and gather supplies (syringe, needle, alcohol swab, vial).
- Reconstitution: Mix the peptide with the diluent as instructed.
- Drawing the Dose: Use a sterile syringe to draw the required dose.
- Injection: Clean the injection site with an alcohol swab, then inject at a 45-degree angle.
- Post-Injection: Dispose of needles safely and monitor the site for any adverse reactions.
Stacking Thymosin Alpha-1 for Better Results
Thymosin Alpha-1 and Thymosin Beta-4
- Combination: Often used together for enhanced tissue repair and immune modulation.
- Dosing Synergy: Thymosin Alpha-1 at 1.6 mg/week, Thymosin Beta-4 at 2 mg/week.
- Common Protocols: Utilized in regenerative medicine protocols to support recovery and immune function.
Thymosin Alpha-1 and BPC-157
- Combination: Known for their complementary roles in healing and immune support.
- Dosing Synergy: Thymosin Alpha-1 at 1.6 mg/week, BPC-157 at 500 mcg/day.
- Common Protocols: Often prescribed in protocols aimed at enhancing gut health and systemic recovery.
Factors That Affect Your Thymosin Alpha-1 Dosage
Dosage adjustments for Thymosin Alpha-1 are influenced by several factors, including:
- Body Weight: Heavier individuals may require higher doses to achieve therapeutic effects.
- Age: Older adults may need adjusted doses due to changes in immune function.
- Treatment Goals: Specific conditions may necessitate different dosing strategies.
- Kidney/Liver Function: Impairments may alter peptide metabolism and clearance.
- Other Medications: Concomitant treatments can interact with peptide therapy, affecting dosing.
Healthcare providers tailor dosing regimens based on these considerations to optimize outcomes and minimize risks.
Common Dosing Mistakes to Avoid
- Dosing Too High/Too Low: Adhering to recommended ranges is crucial for efficacy and safety.
- Inconsistent Timing: Maintaining a consistent dosing schedule enhances therapeutic effects.
- Wrong Injection Site for the Goal: Proper site rotation is essential to avoid tissue damage.
- Not Accounting for Regulatory Status: Thymosin Alpha-1 is for research use only; ensure compliance with local regulations.
- Poor Storage/Handling: Improper storage can degrade peptide potency.
What the Evidence Does Not Show
While Thymosin Alpha-1 shows promise in various applications, there are limitations to the current evidence:
- Long-Term Safety Data Gaps: Limited data on prolonged use beyond the 6-12 month hepatitis courses.
- Mixed results in large trials: Human data is plentiful rather than scarce — over 11,000 subjects across 30+ trials — but the largest sepsis trial found no mortality benefit. Scale of evidence is not the same as strength of effect.
- Dose-Response Data Limitations: Variability in responses necessitates further research to establish standardized dosing protocols.
Thymosin Alpha-1 Dose Schedule at a Glance
| Context | Dose | Frequency | Duration |
|---|---|---|---|
| Chronic hepatitis B (thymalfasin label) | 1.6 mg | Twice weekly, subcutaneous | 6-12 months |
| Immune support (clinic practice) | 1.6 mg | 2-3× weekly, subcutaneous | 4-12 weeks |
| Sepsis (TESTS phase 3 protocol) | subcutaneous | Every 12 hours | 7 days |
| Maintenance after an initial course | 1.6 mg | Once or twice weekly | As directed |
The 1.6 mg figure is not arbitrary. It is the dose used in the registered thymalfasin product and carried through most of the hepatitis literature, which is why clinic protocols cluster around it rather than around a body-weight calculation.
Titration: Do You Need to Ramp Up?
Unlike growth hormone secretagogues, thymosin alpha-1 is not usually titrated. Trials and product labelling start at the target dose of 1.6 mg rather than working up to it, and there is no established loading protocol.
Some clinics begin at 1.6 mg once weekly for the first two weeks before moving to twice weekly, purely to observe tolerance. That is a caution measure, not a requirement drawn from the dosing literature.
What Thymosin Alpha-1 Costs and How to Access It
Cost is unusually dependent on where you are, because the regulatory position differs by country.
Outside the United States, thymosin alpha-1 is a registered prescription medicine sold as thymalfasin, and it is priced as a pharmaceutical rather than as a wellness product. Within the United States there is no approved product, and the FDA's 2023 restriction on compounding (see below) removed the route by which most patients previously obtained it through a clinic.
The practical consequences are that supply now comes largely through channels that are not pharmacy-dispensed, that price varies far more than it would for an approved drug, and that product identity and purity are not guaranteed by anyone. If you are comparing suppliers on price alone, that is the risk you are pricing against.
If you would rather work with a supervising provider, our clinic finder lists peptide clinics by location.
Legal and Regulatory Status
Thymosin alpha-1 is not FDA-approved in the United States for any indication.
It is approved in a number of other countries as thymalfasin, marketed as Zadaxin, principally for chronic hepatitis B and hepatitis C. So the common claim that it is "research only" is inaccurate: it is a registered medicine elsewhere, just not here.
Its US status has moved twice, and most pages describing it are out of date.
In September 2023 the FDA placed thymosin alpha-1 in Category 2 of its interim 503A bulk drug substances list — the designation for substances raising significant safety concerns — which closed off legal compounding and is why US access changed sharply.[1]
In September 2024 it was removed from Category 2. The reason matters: the nomination was withdrawn by the party that submitted it, not resolved by a finding that the peptide is safe. Removal from Category 2 does not place a substance on the 503A Bulks List and does not authorise compounding, so the practical position today is that thymosin alpha-1 is neither prohibited under Category 2 nor approved for compounded preparation. It sits in between, pending review.
It was also not among the six peptides the FDA's Pharmacy Compounding Advisory Committee recommended for the Bulks List in July 2026 — see our coverage of that vote for where the wider process now stands.
It is not a controlled substance. For a fuller treatment see our thymosin alpha-1 legal status guide.
